FDA Approvals, News & UpdatesLung Cancer

Tecentriq plus Chemotherapy Approved for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

April 2019 Vol 5 No 2

In March 2019, the FDA approved the use of the immunotherapy Tecentriq (atezolizumab; from Genentech), a PD-L1 inhibitor, in combination with a chemotherapy regimen as first-line treatment of patients with extensive-stage small-cell lung cancer. Tecentriq was previously approved for bladder (urothelial) cancer, non–small-cell lung cancer (or NSCLC), and in March 2019, for triple-negative breast cancer (read more).

This new approval was based on the results of a clinical trial of 403 patients who had not received chemotherapy for extensive-stage small-cell lung cancer. In this study, patients received either Tecentriq plus chemotherapy or placebo plus chemotherapy. The average survival was 3 months longer with the combination of immunotherapy plus chemotherapy, for a total of 12.3 months in the Tecentriq group versus 10.3 months in the placebo group. The average time without cancer progression was 5.2 months in patients who received Tecentriq plus chemotherapy versus 4.3 months in those who received placebo plus chemotherapy.

The most common side effects in the Tecentriq plus chemotherapy group were fatigue, nausea, hair loss (alopecia), constipation, and decreased appetite.

Recommended For You
Lung Cancer
Drugs for Lung Cancer
Here are the drugs and financial support services available to patients receiving treatment for Lung Cancer.
Genetics & CancerLung CancerPatient Stories
Using My Lung Cancer Story to Advocate for Change in Minority Communities
By Brandi Bryant
After getting tested for genetic abnormalities, Brandi Bryant learned she had the ALK genetic mutation, which increases the risk for lung cancer. This information resulted in important changes in her treatment and led her to become an advocate for genetic testing, especially among minority communities.
Lung Cancer
Tecentriq plus Chemotherapy Approved as First Therapy for Metastatic Lung Cancer without EGFR or ALK Mutations
Late in 2019, the FDA approved the combination of immunotherapy plus chemotherapy as the first-line treatment for patients with non–small-cell lung cancer that does not harbor EGFR or ALK mutations, which are often associated with lung cancer.
Lung Cancer
What Do I Need to Know? A Guide for the Newly Diagnosed Person with Lung Cancer
By Claudia T Miller, BSN, RN, OCN, ONN-CG
The treatment landscape of lung cancer has changed dramatically in the past 5 years. New immunotherapies have significantly improved survival. Learn about your diagnosis and the current treatment options.
Last modified: June 3, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.